DMAC
What one share of DiaMedica Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from severe ischemic disease with two main clinical programs focused on preeclampsia (PE) / fetal growth restriction (FGR) and acute ischemic stroke (AIS).
DiaMedica Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.72 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.60 |
| Cash and investments | $0.81 |
| Book value | $0.71 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$0.72 | $0.00 | −$0.66 | — | $0.13 |
| 2018 | $0.06 | −$0.74 | $0.01 | −$0.74 | — | $1.42 |
| 2019 | — | −$0.89 | $0.00 | −$0.76 | — | $0.63 |
| 2020 | — | −$0.78 | $0.00 | −$0.59 | — | $1.39 |
| 2021 | — | −$0.65 | $0.00 | −$0.59 | — | $1.66 |
| 2022 | — | −$0.52 | $0.00 | −$0.44 | — | $1.20 |
| 2023 | — | −$0.60 | $0.00 | −$0.58 | — | $1.35 |
| 2024 | — | −$0.60 | $0.00 | −$0.55 | — | $0.95 |
| 2025 | — | −$0.70 | $0.00 | −$0.62 | — | $1.04 |